Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desipramine is a secondary amine tricyclic antidepressant (TCA) primarily used for the treatment of depression. It acts mainly by selectively inhibiting the reuptake of norepinephrine (noradrenaline) at neuronal synapses, thereby increasing its concentration in the brain and enhancing neurotransmission. It also inhibits serotonin reuptake to a lesser extent compared to other TCAs such as imipramine. Chronic use leads to down-regulation of beta adrenergic receptors and sensitization of serotonergic receptors, contributing to its antidepressant effects. Additionally, desipramine exhibits minor anticholinergic activity due to affinity for muscarinic receptors. Off-label uses include bulimia nervosa, irritable bowel syndrome, neuropathic pain, overactive bladder, post-herpetic neuralgia, ADHD, agitation and insomnia[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desipramine.